NU
NUVB.US Nuvation Bio Inc
- Market cap
- USD 1.41B
- P/E
- -
- P/B
- 6.18x
- ROE
- -58.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NUVB.US undervalued?
Graham numberThe Graham number of Nuvation Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nuvation Bio Inc fundamental analysis
No fundamental analysis for Nuvation Bio Inc yet.
Nuvation Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safu…
Full company profileNuvation Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nuvation Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 7.87M | 62.9M | 213M |
| Gross Profit | - | - | -103K | -368K | -484K | -222K | 795K | 54.5M | 189M |
| Operating Income | -992K | -32.1M | -43.6M | -93.3M | -120M | -99.8M | -593M | -213M | -119M |
| EBITDA | - | -32.1M | -41.6M | -86.7M | -104M | -75.6M | -567M | -189M | -104M |
| Net Income | -992K | -33.6M | -41.7M | -86.8M | -104M | -75.8M | -568M | -205M | -132M |
| EPS | -0.01 | -0.16 | -0.19 | -0.44 | -0.48 | -0.35 | -2.11 | -0.60 | -0.38 |
| Balance Sheet | |||||||||
| Total Assets | 158K | 121M | 222M | 776M | 672M | 621M | 541M | 595M | 778M |
| Total Liabilities | 902K | 3.20M | 6.71M | 30.2M | 17.1M | 16.4M | 76.8M | 289M | 550M |
| Shareholders' Equity | -744K | 118M | 215M | 746M | 655M | 605M | 464M | 306M | 228M |
| Cash & Short-term Investments | 138K | 119M | 216M | 765M | 661M | 611M | 503M | 529M | 663M |
| Total Debt | 600K | - | - | 3.06M | 4.26M | 4.01M | 8.92M | 10.1M | 468M |
| Cash Flow | |||||||||
| Operating Cash Flow | -616K | -24.4M | -36.5M | -68.2M | -96.1M | -68.0M | -130M | -173M | -102M |
| Capital Expenditure | 659K | 659K | 145K | 282K | 370K | 69.0K | 162K | 354K | 2.52M |
| Free Cash Flow | -1.28M | -25.1M | -36.7M | -68.5M | -96.5M | -68.1M | -131M | -174M | -104M |
| Ratios | |||||||||
| ROE | - | -28.5% | -19.4% | -11.6% | -15.9% | -12.5% | -122.5% | -66.9% | -58.1% |
| ROA | -627.8% | -27.7% | -18.8% | -11.2% | -15.5% | -12.2% | -105.1% | -34.4% | -17.0% |
| Net Profit Margin | - | - | - | - | - | - | -7,213.8% | -325.3% | -62.1% |
| Debt to Equity | - | - | - | 0.00x | 0.01x | 0.01x | 0.02x | 0.03x | 2.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nuvation Bio Inc dividends
Nuvation Bio Inc has not paid dividends in the last 8 fiscal years.
Who owns Nuvation Bio Inc
- Insiders 17.37%
- Institutions 71.96%
- Public & others 10.68%
- Shares outstanding 352M
- Free float 266M
Nuvation Bio Inc company profile
- Company name
- Nuvation Bio Inc
- Ticker
- NUVB.US
- Exchange
- USA Stocks
- Listed since
- Aug 24, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 310
- Fiscal year end
- December
- Address
- 1500 Broadway, New York, NY, United States, 10036
- Phone
- 332 208 6102
- Website
- nuvationbio.com
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc management
10- Dr. David T. Hung M.D.Founder, President, CEO & Chairman · born 1958
- Mr. Philippe Pierre SauvageCFO & Principal Financial Officer · born 1978
- Dr. Gary Hattersley Ph.D.Chief Scientific Officer · born 1967
- Mr. Moses Makunje CPAVP of Finance and Principal Accounting & Financial Officer · born 1979
- Dr. David C. Hanley Ph.D.Chief Technical Operations Officer · born 1970
- Robert DeVitaVice President of Corporate Development & Investor Relations
- Dr. Stephen Dang Ph.D.Chief Legal Officer & Corporate Secretary
- Ms. Stacy MarkelChief People Officer · born 1965
- Ms. Kerry A. WentworthChief Regulatory Officer · born 1973
- Ms. Colleen SjogrenChief Commercial Officer · born 1971